Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q3 FY25 results · Oct–Dec 2024
Solara Active Pharma Sciences reported revenue from operations of ₹300.31 crore (up 20.7% from Q3 FY24) and net profit of ₹8.09 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 300.31 | 248.73 | +20.7% | 346.95 | −13.4% |
| Other income | 1.49 | 0.45 | +231.1% | 0.32 | +365.6% |
| Total income | 301.80 | 249.18 | +21.1% | 347.27 | −13.1% |
| Profit before tax | 8.09 | (275.34) | Turned profit | 8.01 | +1.0% |
| Net profit for the period | 8.09 | (275.34) | Turned profit | 8.01 | +1.0% |
| EPS, basic (₹) | 2.03 | (76.49) | not comparable | 2.54 | −20.1% |
| Net margin (%) | 2.7 | -110.7 | 2.3 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 300.31 | 248.73 | +20.7% | 346.95 | −13.4% |
| Other income | 1.49 | 0.44 | +238.6% | 0.32 | +365.6% |
| Total income | 301.80 | 249.17 | +21.1% | 347.27 | −13.1% |
| Profit before tax | 8.10 | (275.33) | Turned profit | 8.02 | +1.0% |
| Net profit for the period | 8.10 | (275.33) | Turned profit | 8.02 | +1.0% |
| EPS, basic (₹) | 2.47 | (76.49) | not comparable | 2.11 | +17.1% |
| Net margin (%) | 2.7 | -110.7 | 2.3 |
Consolidated
- Filed with BSE
- 24 Jan 2025, 19:35 IST
- Board meeting
- 24 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jan 2025, 19:35 IST
- Board meeting
- 24 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE